Regular Article
Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?

https://doi.org/10.1006/scbi.1997.0071Get rights and content

Abstract

The discovery of the Multidrug Resistance-associated Protein (MRP or MRP1) as a GS-X pump able to transport both anionic drug conjugates and unmodified anti-cancer drugs out of the cell, has raised the question whether other members of the MRP family might contribute to drug resistance of human tumours. The most extensively studied member of this family is cMOAT, the canalicular Multispecific Organic Anion Transporter. The substrate specificity of this pump was originally defined by an inborn error in rats, lacking this protein. These rats are mildly hyperbilirubinemic, because of their inability to secrete bilirubin glucuronides into their bile. In addition, they have diminished capacity to secrete a variety of other organic anions. Absence of cM OAT in humans results in an analogous inborn error of metabolism, the Dubin–Johnson syndrome. Attempts to determine the effect of cMOAT on the sensitivity of cells to anti-cancer drugs have run into technical problems. Most cells transfected with a cMOAT cDNA construct and overproducing cMOAT seem unable to transport the protein to the cell surface and are not MDR. However, in polarized kidney cell monolaye rs cMOAT is correctly routed to the apical cell surface and able to transport vinb lastine. Hence, overexpression of cMOAT in cancer cells could potentially lead to drug r esistance. In studies of cells selected for drug resistance no correlation was found thus far between cMOAT overexpression and MDR, but there was a positive association with cisplatin resistance, raising the possibility that cMOAT might contribute to cisplatin resistance by mediating excretion of cisplatin-glutathione complexes. This remains to be verified by more direct experiments and clinical studies, however. Database searches have yielded four additional MRP family members, MRP3-6. The physiological functions of these putative transporters are not yet known and whether they can contribute to drug resistance needs to be determined. Another putative transporter found in many MDR cells not overproducing P-glycoprotein is the Lung Resistance Protein (LRP), which is the major vault protein. Scheperet alhave detected LRP in many MDR cell lines and they have shown that elevated LRP values are a strong and independent predictor of unfavourable outcome for several types of drug-treated human tumours. LRP is a cytoplasmic protein and attempts to demonstrate its involvement in drug transport have failed thus far. The possibility that this protein is only an indicator of resistance caused by upregulation of other proteins, rather than a drug transporter, remai ns open.

References (0)

Cited by (83)

  • A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships

    2022, European Journal of Medicinal Chemistry
    Citation Excerpt :

    As depicted in (Fig. 18), MDR is acquired due to the overexpression of drug transport proteins like P-gp [160] and ABCB1 [161] which are responsible for the expulsion of anti-cancer agents and become a major cause for failure of chemotherapy [162]. [163]. Recent studies showed that MDR-associated protein (MRP), lung resistant protein (LRP) [164] and mutation of DNA topoisomerase II lead to enhanced cell resistance to anti-cancer drugs [165] which are expressed by tumor cells as MDR [166]. [167]. Search for an effective substrate or antagonist for these drug transporter proteins is being carried out [168].

  • Cisplatin resistance and opportunities for precision medicine

    2016, Pharmacological Research
    Citation Excerpt :

    MRP2, also known as cMOAT (canalicular multispecific organic anion transporter), is the most favored MRP transporter contributing to cisplatin resistance. Overexpression of MRP2 is found in a variety of cisplatin resistant cells lines [107–109]. The expression of MRP2 is induced by cisplatin as well [110].

  • The role of ABC transporters in ovarian cancer progression and chemoresistance

    2015, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    ABCC2 (MRP-2), the canalicular multispecific organic anion transporter (cMOAT), is ∼190 kDa and has 49% AA identity with ABCC1 [191]. It is thought to have a physiological role as an organic anion pump in the liver and play a role in detoxification of alkylating agents in the apical epithelium of the liver and kidney [192,193]. ABCC2 positivity varies from 16% to 100% in ovarian cancer tissue cohorts [91,114,194,195] (Table 4).

  • Synthesis of some novel benzofuran-2-yl(4,5-dihyro-3,5-substituted diphenylpyrazol-1-yl) methanones and studies on the antiproliferative effects and reversal of multidrug resistance of human MDR1-gene transfected mouse lymphoma cells in vitro

    2011, European Journal of Medicinal Chemistry
    Citation Excerpt :

    The multidrug resistance of cancer cells is often associated with the over expression of P-glycoprotein (P-gp). Recent studies showed that tumor cells expressing MDR-associated protein (MRP), lung resistant protein (LRP) and mutation of DNA topoisomerase II are likely to be MDR [4,5]. Although several mechanisms have been reported, MDR results mainly from the over expression of ATP-binding cassette (ABC) transporters, such as, ABCB1 (P-glycoprotein, P-gp), ABCC1–7 (multidrug resistant related protein 1–7, MRP1–7) and ABCG2 (breast cancer resistance protein, BCRP), which pump out a enormous number of chemically dissimilar anticancer agents.

  • Physiological, pharmacological and clinical features of the multidrug resistance protein 2

    2005, Biomedicine and Pharmacotherapy
    Citation Excerpt :

    MRP2 plays an important role in the membrane transport of various drugs, including organic anions and anticancer agents, particularly at the biliary pole of hepatocytes. By this way, MRP2 is thought to be one of the major membrane transporters involved in the pharmacokinetic profile of drugs [7–9]; in addition, it may be involved in anticancer drug resistance [10]. MRP2 also handles endogenous compounds and alteration of this physiological function can lead to clinical disorders [11].

View all citing articles on Scopus
View full text